← Back to feedRead original →
VERIFIEDET Stocks·positive
Laurus Labs shifts gears as CDMO emerges as key growth driver; Nuvama sees 24% upside
AI Summary
- ·Nuvama Institutional Equities initiated coverage on Laurus Labs with a 'Buy' rating.
- ·The target price set by Nuvama is Rs 2,520, indicating a potential 24% upside.
- ·Nuvama expects Laurus Labs' growth to be driven by a shift towards its CDMO business.